公开(公告)号：WO2016155506A1

公开(公告)日：2016-10-06

申请号：PCT/CN2016/076593

申请日：2016-03-17

Applicant: 李翀

Inventor： 李翀

IPC: C07K14/705 ,  C07K16/30 ,  G01N33/577 ,  G01N33/574 ,  C12N5/20

CPC classification number: C07K14/7055 ,  A61K47/6857 ,  A61K49/1875 ,  A61P35/00 ,  C07K14/705 ,  C07K16/2842 ,  C07K16/3023 ,  C07K16/44 ,  C07K2317/14 ,  G01N33/574 ,  G01N33/57423 ,  G01N33/577 ,  G01N2800/7028

Abstract: 本发明提供了一种人肺癌标志物N3G4，及其作为人肺癌标志物的用途。本发明还提供了产生抗N3G4的单克隆抗体的杂交瘤细胞，及其分泌的单克隆抗体LC128，及LC128用于制备肺癌诊断剂的用途。本发明还提供了包含单克隆抗体LC128的体外诊断试剂盒和使用单克隆抗体LC128检测肺组织中肿瘤标志物的方法。

公开(公告)号：WO2014163222A1

公开(公告)日：2014-10-09

申请号：PCT/KR2013/002847

申请日：2013-04-05

Applicant: INTRON BIOTECHNOLOGY, INC.

Inventor： LEE, Kwang Yeol ,  KIM, Min Sik ,  KIM, Taek Hoon ,  VU, Ngoc Phan

IPC: A61K49/06 ,  A61K49/04 ,  A61K47/02 ,  A61K9/16

CPC classification number: A61K49/186 ,  A61K49/1818 ,  A61K49/1875 ,  B01J20/06 ,  B01J20/28016 ,  B01J23/8892 ,  B01J35/0013 ,  H01M4/364 ,  H01M4/50 ,  H01M4/52 ,  H01M4/8652 ,  H01M4/9016

Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MRI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis.

Abstract translation: 本发明涉及磁共振成像（MRI）造影剂，特别是衍生自纳米颗粒的MRI造影剂，其是具有中心腔的多孔第一金属掺杂的第二金属氧化物纳米颗粒及其制造方法。 根据本发明制备的MRI造影剂不仅可以用作治疗药物递送剂，而且可以用作用于诊断的MRI造影剂。

公开(公告)号：WO2012105794A3

公开(公告)日：2012-10-26

申请号：PCT/KR2012000739

申请日：2012-01-31

Applicant: UNIV KOREA RES & BUS FOUND ,  KIM YOUNG KEUN ,  WU JUN HUA ,  MIN JI HYUN ,  LEE JI-SUNG ,  JUNG JAE-HO

Inventor： KIM YOUNG KEUN ,  WU JUN HUA ,  MIN JI HYUN ,  LEE JI-SUNG ,  JUNG JAE-HO

IPC: A61K9/16 ,  A61K47/02 ,  A61K47/48 ,  A61K49/08

CPC classification number: G01N27/72 ,  A61K49/1827 ,  A61K49/1851 ,  A61K49/1866 ,  A61K49/1875 ,  C01G45/12 ,  C01P2002/72 ,  C01P2002/85 ,  C01P2004/04 ,  C01P2004/62 ,  C01P2004/64 ,  C01P2006/42 ,  G01N33/587

Abstract: The present invention relates to a magnetic nanoparticle having a Curie temperature which is within the biocompatible temperature range, to a method for preparing same, and to a nanocomposite and a target-substance-detecting composition comprising the magnetic nanoparticle. As the magnetic nanoparticle of the present invention has a Curie temperature within the temperature range of 0°C to 41°C, the ferromagnetic and paramagnetic properties of the magnetic nanoparticle may be controlled within a biocompatible temperature range at a temperature at which a biological control agent is not destroyed, and the temperature of the magnetic nanoparticle is adjusted to control the magnetic properties thereof such that the properties of the magnetic nanoparticle may be used only when ferromagnetic properties are required, such as in the case of signal amplification in detecting, separating, and delivering biological control agents. Accordingly, the magnetic nanoparticle of the present invention may minimize adverse effects caused by the ferromagnetic properties thereof, and may be used in the effective detection and separation of biological control agents.

Abstract translation: 本发明涉及具有在生物相容性温度范围内的居里温度的磁性纳米粒子，其制备方法，以及包含该磁性纳米粒子的纳米复合材料和靶物质检测组合物。 由于本发明的磁性纳米粒子具有在0℃至41℃的温度范围内的居里温度，所以可以将磁性纳米粒子的铁磁性和顺磁性控制在生物相容性温度范围内， 试剂不被破坏，并且调节磁性纳米粒子的温度以控制其磁性，使得仅当需要铁磁性时才能使用磁性纳米粒子的性质，例如在检测时的信号放大，分离 ，并提供生物控制剂。 因此，本发明的磁性纳米粒子可以使由其铁磁性质引起的不利影响最小化，并且可以用于生物防治剂的有效检测和分离。

公开(公告)号：WO2011156296A1

公开(公告)日：2011-12-15

申请号：PCT/US2011/039349

申请日：2011-06-07

Applicant: SCIENTIFIC NANOMEDICINE, INC. ,  FLYNN, Edward, R.

Inventor： FLYNN, Edward, R.

IPC: A61M37/00 ,  A61N2/00

CPC classification number: A61B5/05 ,  A61B5/4836 ,  A61B5/4839 ,  A61B5/4848 ,  A61K41/0052 ,  A61K49/1851 ,  A61K49/1875 ,  A61N1/403 ,  A61N2/02 ,  A61N2/12

Abstract: Embodiments of the present invention provide methods of detecting cancer, methods of treating cancer using targeted hyperthermia, methods of treating cancer using targeted chemical agents, methods of treating cancer comprising accurate measurements of the efficacy of treatments. The effect of nanoparticles on magnetic fields can be used to determine the location of a tumor, and a measure of the number of cells in the tumor. This location and measure can be used to guide therapy, and provide information regarding the most effective therapy to be applied. The same nanoparticles can be used to facilitate hyperthermia treatments, and to allow targeted application of chemical therapeutic agents.

Abstract translation: 本发明的实施方案提供了检测癌症的方法，使用靶向高热治疗癌症的方法，使用靶向化学药剂治疗癌症的方法，治疗癌症的方法，包括治疗效果的精确测量。 纳米颗粒对磁场的影响可用于确定肿瘤的位置以及肿瘤中细胞数量的测量。 该位置和措施可用于指导治疗，并提供有关最有效治疗的信息。 可以使用相同的纳米颗粒来促进热疗治疗，并允许靶向施用化学治疗剂。

公开(公告)号：WO2011053901A2

公开(公告)日：2011-05-05

申请号：PCT/US2010054939

申请日：2010-11-01

Applicant: UNIV NORTHWESTERN ,  DRAVID VINAYAK P ,  SHARMA SAURABH ,  TOMITA TADANORI ,  VIOLA KIRSTEN L ,  KLEIN WILLIAM L

Inventor： DRAVID VINAYAK P ,  SHARMA SAURABH ,  TOMITA TADANORI ,  VIOLA KIRSTEN L ,  KLEIN WILLIAM L

IPC: G01N33/53 ,  A61K49/16 ,  G01N27/72 ,  G01N33/574

CPC classification number: A61K47/6923 ,  A61K41/0052 ,  A61K47/48623 ,  A61K47/6865 ,  A61K49/1833 ,  A61K49/186 ,  A61K49/1875 ,  A61N2/004 ,  B82Y5/00

Abstract: The present invention relates to magnetic nanostructures as theranostic agents, which provide dual function as diagnostic and therapeutic agents. In particular, the present invention relates to compositions comprising magnetic nanostructures and their use as targeted therapeutic agents for cancers (e.g., medulloblastoma) and Alzheimer's disease and related diseases and conditions.

Abstract translation: 本发明涉及作为诊断剂的磁性纳米结构，其提供了作为诊断剂和治疗剂的双重功能。 具体而言，本发明涉及包含磁性纳米结构的组合物及其作为癌症（例如成神经管细胞瘤）和阿尔茨海默氏病及相关疾病和病症的靶向治疗剂的用途。

公开(公告)号：WO2009120702A3

公开(公告)日：2009-12-23

申请号：PCT/US2009038112

申请日：2009-03-24

Applicant: UNIV EMORY ,  UNIV DELAWARE ,  HADJIPANAYIS CONSTANTINOS G ,  HADJIPANAYIS GEORGE C ,  BONDER MICHAEL J

Inventor： HADJIPANAYIS CONSTANTINOS G ,  HADJIPANAYIS GEORGE C ,  BONDER MICHAEL J

IPC: B82B1/00 ,  C01G49/00

CPC classification number: G01N33/54326 ,  A61K49/16 ,  A61K49/1854 ,  A61K49/1875 ,  B82Y5/00 ,  G01N33/574

Abstract: Synthesis of iron nanoparticles with a substantially unoxidized iron core and a biocompatible coating is described. The nanoparticles are formed by reacting an iron salt solution with a reducing agent in a substantially oxygen-free environment and exposing the formed iron particles to a biocompatible coating agent in a substantially oxygen-free environment to form coated iron particles. An average diameter of the coated iron particles is between 5 nm and 25 nm. The biocompatible coating can functionalized with cell-specific agents for use as diagnostic and therapeutic agents.

Abstract translation: 描述了具有基本上未氧化的铁芯和生物相容性涂层的铁纳米颗粒的合成。 通过在基本上无氧的环境中使铁盐溶液与还原剂反应形成纳米颗粒，并将形成的铁颗粒在基本上不含氧的环境中暴露于生物相容的涂层剂中以形成涂覆的铁颗粒。 涂覆的铁颗粒的平均直径在5nm和25nm之间。 生物相容性涂层可以用细胞特异性试剂进行功能化，用作诊断和治疗剂。

公开(公告)号：WO2007099289A1

公开(公告)日：2007-09-07

申请号：PCT/GB2007/000526

申请日：2007-02-14

Applicant: MEDICAL RESEARCH COUNCIL ,  JONES, William, Alexander ,  BHAKOO, Kishore, Kumar

Inventor： JONES, William, Alexander ,  BHAKOO, Kishore, Kumar

IPC: G01N33/543

CPC classification number: G01N33/54353 ,  A61K41/00 ,  A61K41/0052 ,  A61K47/6923 ,  A61K49/1875 ,  B82Y5/00

Abstract: Iron oxide nanoparticles comprising functional groups of the formula-X-NH 2 on the outer surface of said nanoparticles, wherein X is selected from O, NR, NH or S, where R is C 1-7 alkyl and conjugate particles comprising an iron oxide nanoparticle linked via a bond of formula-C=N-X-to a cell targeting ligand, where X is selected from O, NR, NH or S, where R is C 1-7 alkyl.

Abstract translation: 在所述纳米颗粒的外表面上包含式-X-NH 2官能团的氧化铁纳米颗粒，其中X选自O，NR，NH或S，其中R是C 1 包含通过式-C = NX的键连接的氧化铁纳米颗粒的偶联颗粒与细胞靶向配体结合，其中X选自O，NR，NH或S，其中R为C < 烷基。

公开(公告)号：WO2007030531A2

公开(公告)日：2007-03-15

申请号：PCT/US2006/034703

申请日：2006-09-06

Applicant: MOLECULAR IMAGE INC. ,  OKLAHOMA MEDICAL RESEARCH FOUNDATION ,  WOHLGEMUTH, Jay, M., D. ,  FRY, Kirk ,  TOWNER, Rheal, Antoine

Inventor： WOHLGEMUTH, Jay, M., D. ,  FRY, Kirk ,  TOWNER, Rheal, Antoine

IPC: A61K49/16

CPC classification number: A61K49/143 ,  A61K49/085 ,  A61K49/16 ,  A61K49/1875 ,  B82Y5/00

Abstract: The present invention describes both the identification of disease target molecules and the development of imaging reagents and diagnostic assays specific to those molecules. Described herein are methods and reagents for the identification of molecular targets specific to a disease or disease state, methods of imaging technology which can be used, the development of specific molecular imaging reagents, clinical validation of the imaging reagents, and clinical indications for molecular imaging.

Abstract translation: 本发明描述了疾病靶分子的鉴定和成像试剂的发展以及对那些分子特异性的诊断测定。 本文描述了用于鉴定特定于疾病或疾病状态的分子靶标的方法和试剂，可以使用的成像技术的方法，特定分子成像试剂的开发，成像试剂的临床验证以及分子成像的临床适应症 。

公开(公告)号：WO0035493A3

公开(公告)日：2000-09-21

申请号：PCT/EP9909925

申请日：1999-12-14

Applicant: WENGLER GEORG S

Inventor： WENGLER GEORG S

IPC: A61K49/08 ,  A61K49/16 ,  A61K49/18 ,  A61K51/12 ,  A61K49/00

CPC classification number: A61K49/1875 ,  A61K49/16

Abstract: The invention relates to a method for localizing sites of disease in human or animal bodies, according to which the patient's immune-defense cells are combined with the corresponding antibodies to form a cell-antibody complex, the antibodies being labelled with contrast particles. The site of disease is determined by means of an imaging method which detects cell-antibody complexes which have migrated to the site of disease in the patient's body.

Abstract translation: 本发明涉及一种用于定位人或动物患者体内疾病病灶的方法，其中患者免疫细胞与细胞 - 抗体复合物相关的抗体相关，其中抗体用对比颗粒标记。 通过成像方法确定疾病的焦点，所述成像方法确定患者体内迁移的细胞 - 抗体复合物中的病原体。

公开(公告)号：WO2018007258A1

公开(公告)日：2018-01-11

申请号：PCT/EP2017/066315

申请日：2017-06-30

Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG

Inventor： ALMANZAR, Giovanni ,  BLEY, Thorsten ,  KÖSTLER, Herbert ,  PRELOG, Martina ,  WECH, Tobias ,  GUTJAHR, Fabian ,  JAKOB, Peter Michael ,  KÜRTEN, Stefanie

IPC: A61K39/395 ,  A61K51/10 ,  A61K49/00 ,  G01N33/533 ,  G01N33/534

CPC classification number: G01N33/533 ,  A61K49/1875 ,  C07K16/2866 ,  G01N33/534

Abstract: The invention concerns immune complexes for use in a diagnostic method for de- tecting and localizing specific cells or a structure of a tissue in a human or animal body by an imaging technique. First antibodies are directed to an antigen located on the tissue or on the surface of said cells. The first antibodies are optionally la- beled with first labels. The method comprises that the first antibodies and second antibodies directed to said first antibodies or to the first labels or the first antibod- ies and ligands specifically binding to the first labels are administered to said hu- man or animal body, wherein said second antibodies or said ligands are labeled with second labels detectable by said imaging technique. The structure of the tis- sue or the cells is/are detected and localized in the human or animal body after ad- ministration of the first antibodies and second antibodies or of the first antibodies and the ligands by use of the imaging technique. The immune complexes of the in- vention are formed from the first antibodies and the second antibodies or from the first antibodies and the ligands ex vivo before administration of said immune com- plexes to the human or animal body. The ratio of said second antibodies to said first antibodies or of said ligands to said first antibodies in the immune complexes is at least 5 : 1.

Abstract translation: 本发明涉及免疫复合物，其用于通过成像技术检测和定位人或动物体内特定细胞或组织结构的诊断方法中。 第一抗体针对位于组织上或所述细胞表面上的抗原。 第一个抗体可选地标有第一个标签。 该方法包括将针对所述第一抗体或针对第一标记的第一抗体和第二抗体或针对第一抗体的第一抗体和与第一标记特异性结合的配体给予所述人或动物体，其中所述第二抗体或 所述配体用可通过所述成像技术检测的第二标记标记。 在通过使用成像技术给予第一抗体和第二抗体或第一抗体和配体后，检测组织和细胞的结构并将其定位在人体或动物体内。 本发明的免疫复合物在向所述人体或动物体施用所述免疫复合物之前由第一抗体和第二抗体或从第一抗体和配体离体形成。 所述第二抗体与所述第一抗体或所述配体与免疫复合物中所述第一抗体的比例至少为5：1。